Trial Profile
An Open Label Single Oral Dose Study in Patients With Mild Alzheimer's Disease to Assess the Pharmacokinetics of Extended Release Formulation of Rosiglitazone (RSG XR) in This Population
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 31 Aug 2023
Price :
$35
*
At a glance
- Drugs Rosiglitazone (Primary)
- Indications Alzheimer's disease
- Focus Pharmacokinetics
- Sponsors GlaxoSmithKline; GSK
- 27 Oct 2008 Trial phase changed from II to I as reported by ClinicalTrials.gov.
- 27 Oct 2008 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 25 Jun 2008 New trial record.